JP2023082086A5 - - Google Patents

Download PDF

Info

Publication number
JP2023082086A5
JP2023082086A5 JP2023052465A JP2023052465A JP2023082086A5 JP 2023082086 A5 JP2023082086 A5 JP 2023082086A5 JP 2023052465 A JP2023052465 A JP 2023052465A JP 2023052465 A JP2023052465 A JP 2023052465A JP 2023082086 A5 JP2023082086 A5 JP 2023082086A5
Authority
JP
Japan
Prior art keywords
crystalline form
powder
ray diffraction
pharmaceutical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023052465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023082086A (ja
JP7763203B2 (ja
Filing date
Publication date
Priority claimed from JP2019538551A external-priority patent/JP7253491B2/ja
Application filed filed Critical
Publication of JP2023082086A publication Critical patent/JP2023082086A/ja
Publication of JP2023082086A5 publication Critical patent/JP2023082086A5/ja
Application granted granted Critical
Publication of JP7763203B2 publication Critical patent/JP7763203B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023052465A 2016-09-29 2023-03-28 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用 Active JP7763203B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201610866253 2016-09-29
CN201610866253.6 2016-09-29
JP2019538551A JP7253491B2 (ja) 2016-09-29 2017-09-29 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用
PCT/CN2017/104506 WO2018059556A1 (zh) 2016-09-29 2017-09-29 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019538551A Division JP7253491B2 (ja) 2016-09-29 2017-09-29 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用

Publications (3)

Publication Number Publication Date
JP2023082086A JP2023082086A (ja) 2023-06-13
JP2023082086A5 true JP2023082086A5 (enExample) 2023-07-28
JP7763203B2 JP7763203B2 (ja) 2025-10-31

Family

ID=61763329

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019538551A Active JP7253491B2 (ja) 2016-09-29 2017-09-29 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用
JP2023052465A Active JP7763203B2 (ja) 2016-09-29 2023-03-28 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019538551A Active JP7253491B2 (ja) 2016-09-29 2017-09-29 キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用

Country Status (17)

Country Link
US (3) US11053224B2 (enExample)
EP (1) EP3502105B8 (enExample)
JP (2) JP7253491B2 (enExample)
KR (1) KR102289684B1 (enExample)
CN (1) CN108884080B (enExample)
AU (1) AU2017336889B2 (enExample)
CA (2) CA3035124C (enExample)
EA (1) EA201990688A1 (enExample)
ES (1) ES2914294T3 (enExample)
IL (2) IL265266B2 (enExample)
MY (1) MY194364A (enExample)
PH (1) PH12019500681A1 (enExample)
PL (1) PL3502105T3 (enExample)
SG (1) SG11201901962QA (enExample)
TW (1) TWI647224B (enExample)
WO (1) WO2018059556A1 (enExample)
ZA (1) ZA201901717B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018059556A1 (zh) * 2016-09-29 2018-04-05 贝达药业股份有限公司 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3171563A1 (en) 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor
CN115531352B (zh) 2020-09-14 2025-04-25 视点制药公司 可生物蚀解的眼部药物递送插入剂及治疗方法
BR112023018649A2 (pt) * 2021-03-16 2023-10-10 Hk Inno N Corp Forma cristalina e método para preparar uma forma cristalina
JP7138982B1 (ja) 2021-09-24 2022-09-20 東海物産株式会社 アンセリンの結晶及びその製造方法
CA3245205A1 (en) 2022-03-11 2023-09-14 EyePoint Pharmaceuticals, Inc. METHOD FOR PREVENTING AGE-RELATED MACULAR DEGENERATION BY ADMINISTRATION OF A DRUG-DELIVERING OPHTHALMIC INSERT
TW202345804A (zh) 2022-03-11 2023-12-01 美商視點製藥有限公司 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法
TW202400143A (zh) 2022-03-11 2024-01-01 美商視點製藥有限公司 用於治療眼睛病況之持續給藥方案
TW202448436A (zh) 2023-04-11 2024-12-16 美商視爾普斯眼科公司 含有酪胺酸激酶抑制劑之眼部植入物
CN117143083A (zh) * 2023-08-30 2023-12-01 沈阳药科大学 VEGFR抑制剂Vorolanib的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0213185A (pt) 2001-10-10 2004-09-14 Sugen Inc Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase
PL2079727T3 (pl) * 2006-09-15 2016-08-31 Xcovery Inc Inhibitory kinazy
EP2145505A1 (de) * 2007-05-07 2010-01-20 Baumer Electric AG Akustischer wandler
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CA2720943A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
RU2468022C2 (ru) 2008-05-23 2012-11-27 Шанхай Инститьют Оф Фармасьютикал Индастри Производные дигидроиндолона
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2264027A1 (en) 2009-05-27 2010-12-22 Ratiopharm GmbH Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
CN106928114B (zh) * 2015-12-31 2020-07-28 韶远科技(上海)有限公司 含有脲基的环状手性氨基类化合物及其可放大工艺和用途
WO2018059556A1 (zh) 2016-09-29 2018-04-05 贝达药业股份有限公司 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用

Similar Documents

Publication Publication Date Title
JP2023082086A5 (enExample)
JP2021530565A5 (enExample)
JP2020512316A5 (enExample)
CN1227233C (zh) 纯晶形的5-氯-3-(4-甲磺酰基苯基)-6′-甲基-[2,3′]联吡啶及其合成方法
JP2005503386A5 (enExample)
JP2023002516A5 (enExample)
JP2009521414A5 (enExample)
JP2023036708A5 (enExample)
JP2017061526A5 (enExample)
JP2022183220A5 (enExample)
JP2021514967A5 (enExample)
JP2019504103A5 (enExample)
JP2019516749A5 (enExample)
JP2007532560A5 (enExample)
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
CN102964384B (zh) 阿德福韦酯没食子酸共晶及其制备方法和组合物
JP2011515421A5 (enExample)
JP2016510767A5 (enExample)
CN111278820A (zh) 一种吡啶酮化合物的晶型、盐型及其制备方法
JP2017503016A5 (enExample)
CA2447878C (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
CN113348166A (zh) 喹啉衍生物的结晶
JP2018024683A5 (enExample)
JPWO2020118113A5 (enExample)
JP2019500385A5 (enExample)